Literature DB >> 18287241

Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.

Natasha M Girgis1, Brian C Dehaven, Xin Fan, Kendra M Viner, Mohammad Shamim, Stuart N Isaacs.   

Abstract

The vaccinia virus (VACV) complement control protein (VCP) is the major protein secreted from VACV-infected cells. It has been reported that VCP binds to the surfaces of uninfected cells by interacting with heparan sulfate proteoglycans (HSPGs). In this study, we show that VCP is also expressed on the surfaces of infected cells and demonstrate that surface localization occurs independently of HSPGs. Since VCP does not contain a transmembrane domain, we hypothesized that VCP interacts with a membrane protein that localizes to the infected-cell surface. We show that the VACV A56 membrane protein is necessary for the cell surface expression of VCP and demonstrate that VCP and A56 interact in VACV-infected cells. Since the surface expression of VCP was abrogated by reducing agents, we examined the contribution of an unpaired cysteine residue on VCP to VCP surface expression and VCP's interaction with A56. To do this, we mutated the unpaired cysteine in VCP and generated a recombinant virus expressing the altered form of VCP. Following the infection of cells with the mutant virus, VCP was neither expressed on the cell surface nor able to interact with A56. Importantly, the cell surface expression of VCP was found to protect infected cells from complement-mediated lysis. Our findings suggest a new function for VCP that may be important for poxvirus pathogenesis and impact immune responses to VACV-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287241      PMCID: PMC2293032          DOI: 10.1128/JVI.02426-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  The formation and function of extracellular enveloped vaccinia virus.

Authors:  Geoffrey L Smith; Alain Vanderplasschen; Mansun Law
Journal:  J Gen Virol       Date:  2002-12       Impact factor: 3.891

2.  Inhibition of the complement cascade by the major secretory protein of vaccinia virus.

Authors:  G J Kotwal; S N Isaacs; R McKenzie; M M Frank; B Moss
Journal:  Science       Date:  1990-11-09       Impact factor: 47.728

3.  Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization.

Authors:  S L Harris; I Frank; A Yee; G H Cohen; R J Eisenberg; H M Friedman
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  Compact, synthetic, vaccinia virus early/late promoter for protein expression.

Authors:  S Chakrabarti; J R Sisler; B Moss
Journal:  Biotechniques       Date:  1997-12       Impact factor: 1.993

5.  E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses.

Authors:  M W Carroll; B Moss
Journal:  Biotechniques       Date:  1995-09       Impact factor: 1.993

6.  Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.

Authors:  M Saifuddin; T Hedayati; J P Atkinson; M H Holguin; C J Parker; G T Spear
Journal:  J Gen Virol       Date:  1997-08       Impact factor: 3.891

7.  Characterization of vaccinia virus glycoproteins by monoclonal antibody precipitation.

Authors:  L G Payne
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

8.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence.

Authors:  S N Isaacs; G J Kotwal; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

9.  Regulation of complement activity by vaccinia virus complement-control protein.

Authors:  R McKenzie; G J Kotwal; B Moss; C H Hammer; M M Frank
Journal:  J Infect Dis       Date:  1992-12       Impact factor: 5.226

10.  Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway.

Authors:  B W Banfield; Y Leduc; L Esford; K Schubert; F Tufaro
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  25 in total

1.  Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

2.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 4.  Poxvirus proteomics and virus-host protein interactions.

Authors:  Kim Van Vliet; Mohamed R Mohamed; Leiliang Zhang; Nancy Yaneth Villa; Steven J Werden; Jia Liu; Grant McFadden
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 5.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

6.  Biological characterization and next-generation genome sequencing of the unclassified Cotia virus SPAn232 (Poxviridae).

Authors:  Priscila P Afonso; Patrícia M Silva; Laila C Schnellrath; Desyreé M Jesus; Jianhong Hu; Yajie Yang; Rolf Renne; Marcia Attias; Richard C Condit; Nissin Moussatché; Clarissa R Damaso
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

7.  Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus.

Authors:  Maria Luiza G Medaglia; Nissin Moussatché; Andreas Nitsche; Pjotr Wojtek Dabrowski; Yu Li; Inger K Damon; Carolina G O Lucas; Luciana B Arruda; Clarissa R Damaso
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

8.  Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.

Authors:  Elizabeth A Moulton; Paula Bertram; Nanhai Chen; R Mark L Buller; John P Atkinson
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 9.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

10.  Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.

Authors:  Jitendra Kumar; Viveka Nand Yadav; Swastik Phulera; Ashish Kamble; Avneesh Kumar Gautam; Hemendra Singh Panwar; Arvind Sahu
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.